For adults 21 and older. Cannabis and hemp-derived cannabinoid laws vary widely by state and municipality; check your local regulations before purchasing.
If you’ve got a sore hand, a stiff knee, or a joint that’s getting worse, you may be wondering whether cannabis products help. Here’s what the evidence supports, what it doesn’t, and how to use them without surprises.
Topicals: the most promising use
In a small randomized trial of people with arthritis at the base of the thumb, a topical CBD gel in shea butter, applied twice daily for two weeks, improved pain and hand function compared with plain shea butter. No adverse events were reported.[1] It was a single-center study of 18 participants, so treat it as promising, not settled.
Topicals aren’t zero-exposure, though. In a 2024 study of five hemp topicals, CBD showed up in the blood and built up over days of twice-daily use, highest with a lotion that contained vitamin E as a skin-penetration enhancer.[2] If you take a blood thinner or other prescription medication, ask your prescribing doctor or pharmacist before using topical CBD products.
Edibles and tinctures: start low, go slow
In a small study of seven regular users, blood THC from commercial edibles peaked between 35 and 90 minutes after eating, and peak levels varied across products.[3] That delay is a known trap. Poison-center reports describe exposures from eating a whole multi-dose product, and researchers have pointed to delayed THC absorption as one driver of rising edible exposures.[4] At one Colorado emergency room, edible-related visits were more often for intoxication (48%) than inhaled-cannabis visits (28%).[5] Start with the lowest dose on the label, wait until past the 90-minute peak window before taking more, and write down what you took and when.
Reading a label
- Third-party lab report (COA) for that exact batch. A lab the brand owns doesn’t count.
- A recent test date.
- A contaminant panel: pesticides, heavy metals, residual solvents, microbes.
- THC content. Hemp topicals can contain THC. In the same 2024 study, nine of 46 people using lotions, a patch, or a gel had THC in saliva at 2 ng/mL or higher, the level the study cites as the federal workplace-test threshold.[2]
- Regulatory status. The FDA has approved one cannabis-derived drug, Epidiolex (CBD), a prescription medicine for specific seizure conditions. Other CBD products are not FDA-approved for any condition.[6]
Check your medications first
Oral CBD can slow the liver enzymes that clear many common drugs.[7] Only about 5% of the studies in a 2025 review tested whether this matters in practice. One case report involves warfarin, a blood thinner. In it, a patient starting a prescription seizure medicine containing CBD needed a nearly 20% warfarin dose cut to keep their blood-clotting test in range.[8] Ask your prescriber or pharmacist before using oral CBD if you take any prescription medicine.
What the evidence doesn’t back
Sleep is a popular reason people try cannabis, and the best data so far points the other way. In a Canadian sleep-clinic study of 1,449 adults, people who used cannabis every day for a year or more woke up more during the night, slept less efficiently, and spent more time in light sleep than non-users.[9] Most patients had sleep apnea, and the study can’t show cause, so treat it as a warning sign, not a verdict.
Inflammation is the other popular claim. The largest review so far, 46 studies and 54,382 people, found cannabis use went with higher levels of both inflammation-promoting and inflammation-calming markers, not a clear drop.[10] In the small CBD trials, the inflammation-promoting markers rose slightly, but not in a way the trials could confirm. So “cannabis reduces inflammation” isn’t clearly supported.
On memory, a large US brain-imaging study of 1,003 young adults, ages 22 to 36, found that heavy lifetime cannabis use was linked to lower brain activity during a memory task. The effect was small, showed up on only one of seven tasks, and doesn’t tell us much about people in their 40s and up.[11]
Bottom line
Topicals have the most support so far, from one small trial, for localized joint pain. Oral products call for more care: start low, check your medications, and buy products with a current third-party lab report. If you have a condition, talk to your clinician first.
References
[1] Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR Jr. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J Hand Surg Am. 2022 Jul. https://doi.org/10.1016/j.jhsa.2022.03.002 ↑︎
[2] Zamarripa CA, Tilton HE, Lin S, et al. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products. J Anal Toxicol. 2024. https://doi.org/10.1093/jat/bkae001 ↑︎ a b
[3] Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control. Pharmaceuticals. 2021 Aug. https://doi.org/10.3390/ph14080817 ↑︎
[4] Characterization of edible marijuana product exposures reported to United States poison centers. Clin Toxicol. 2016. https://doi.org/10.1080/15563650.2016.1209761 ↑︎
[5] Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, et al. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med. 2019. https://doi.org/10.7326/M18-2809 ↑︎
[6] U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process ↑︎
[7] Evidence of Potential Drug Interactions Between Cannabidiol and Other Drugs: A Scoping Review to Guide Pharmaceutical Care. Planta Med. 2025 Aug. https://doi.org/10.1055/a-2593-6351 ↑︎
[8] Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Health Syst Pharm. 2020 Oct. https://doi.org/10.1093/ajhp/zxaa268 ↑︎
[9] Velzeboer et al. Chronic cannabis use and sleep architecture: a cross-sectional analysis of polysomnography outcomes in a sleep-clinic cohort. Sleep. 2026 May. https://doi.org/10.1093/sleep/zsaf396 ↑︎
[10] Belvederi Murri M, Guglielmo R, Zizzi F, et al. Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis. Brain Behav Immun. 2026 Jul. https://doi.org/10.1016/j.bbi.2026.106517 ↑︎
[11] Gowin JL, Ellingson JM, Karoly HC et al. Brain Function Outcomes of Recent and Lifetime Cannabis Use. JAMA Netw Open. 2025. https://doi.org/10.1001/jamanetworkopen.2024.57069 ↑︎

Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.

Leave a Reply